Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin R Flaherty

Showing results (61-70 of 204) with videos related to

Pageof 21
Sort By:
Respiratory Research|February 12, 2020
Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient RegistryColin H Holtze, Elizabeth A Freiheit, Susan L Limb, et al.
American Journal of Respiratory and Critical Care Medicine|June 4, 2013
Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trialsGanesh Raghu, Harold R Collard, Kevin J Anstrom, et al.
American Journal of Respiratory and Critical Care Medicine|April 17, 2012
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trialsGanesh Raghu, Harold R Collard, Kevin J Anstrom, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 27, 2021
Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical PracticeDinesh Khanna, Alain Lescoat, David Roofeh, et al.
BMJ Open Respiratory Research|July 5, 2022
Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosisSteven D Nathan, Jurgen Behr, Vincent Cottin, et al.
American Journal of Respiratory and Critical Care Medicine|June 23, 2016
Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic CriteriaGanesh Raghu, Athol U Wells, Andrew G Nicholson, et al.
Plos One|August 5, 2016
Six-SOMAmer Index Relating to Immune, Protease and Angiogenic Functions Predicts Progression in IPFShanna L Ashley, Meng Xia, Susan Murray, et al.
The European Respiratory Journal|January 24, 2015
Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosisDavid S Wilkes, Terrence Chew, Kevin R Flaherty, et al.
The European Respiratory Journal|December 22, 2023
Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosisMarlies Wijsenbeek, Jeffrey J Swigris, Yoshikazu Inoue, et al.
The Lancet. Respiratory Medicine|December 10, 2016
The diagnosis of idiopathic pulmonary fibrosis: current and future approachesFernando J Martinez, Alison Chisholm, Harold R Collard, et al.
Pageof 21

Showing results (61-70 of 204) with videos related to

Sort By:
Pageof 21
Respiratory Research|February 12, 2020
Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient RegistryColin H Holtze, Elizabeth A Freiheit, Susan L Limb, et al.
American Journal of Respiratory and Critical Care Medicine|June 4, 2013
Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trialsGanesh Raghu, Harold R Collard, Kevin J Anstrom, et al.
American Journal of Respiratory and Critical Care Medicine|April 17, 2012
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trialsGanesh Raghu, Harold R Collard, Kevin J Anstrom, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 27, 2021
Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical PracticeDinesh Khanna, Alain Lescoat, David Roofeh, et al.
BMJ Open Respiratory Research|July 5, 2022
Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosisSteven D Nathan, Jurgen Behr, Vincent Cottin, et al.
American Journal of Respiratory and Critical Care Medicine|June 23, 2016
Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic CriteriaGanesh Raghu, Athol U Wells, Andrew G Nicholson, et al.
Plos One|August 5, 2016
Six-SOMAmer Index Relating to Immune, Protease and Angiogenic Functions Predicts Progression in IPFShanna L Ashley, Meng Xia, Susan Murray, et al.
The European Respiratory Journal|January 24, 2015
Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosisDavid S Wilkes, Terrence Chew, Kevin R Flaherty, et al.
The European Respiratory Journal|December 22, 2023
Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosisMarlies Wijsenbeek, Jeffrey J Swigris, Yoshikazu Inoue, et al.
The Lancet. Respiratory Medicine|December 10, 2016
The diagnosis of idiopathic pulmonary fibrosis: current and future approachesFernando J Martinez, Alison Chisholm, Harold R Collard, et al.
Pageof 21